PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside

The latest announcement is out from PharmaTher Holdings Ltd ( (TSE:PHRM) ).

PharmaTher Holdings Ltd. has entered into an Asset Purchase Agreement to sell its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP to a global pharmaceutical company specializing in sterile injectables and complex generics. This transaction is structured to allow PharmaTher to benefit from future sales in the growing ketamine market, while enabling the company to focus on advancing its next-generation ketamine programs. The agreement, which could potentially generate over $25 million in milestone and profit-sharing payments, positions PharmaTher to maintain exposure to the global ketamine market and pursue high-value opportunities for patients and shareholders.

Spark’s Take on TSE:PHRM Stock

According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.

PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.

To see Spark’s full report on TSE:PHRM stock, click here.

More about PharmaTher Holdings Ltd

PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine for mental health, pain, and neurological disorders.

Average Trading Volume: 228,191

Technical Sentiment Signal: Buy

Current Market Cap: C$33.19M

For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.